Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Open Source Software
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Electrocardiographic features of sarcomere mutation carriers with and without clinically overt hypertrophic cardiomyopathy.
Subtle abnormalities in contractile function are an early manifestation of sarcomere mutations in dilated cardiomyopathy.
T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy.
Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy.
Comparison of echocardiographic and cardiac magnetic resonance imaging in hypertrophic cardiomyopathy sarcomere mutation carriers without left ventricular hypertrophy.
Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression.
Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy.
Evolution of hypertrophic cardiomyopathy in sarcomere mutation carriers.
A Comparison of Whole Genome Sequencing to Multigene Panel Testing in Hypertrophic Cardiomyopathy Patients.
Intrinsic mitral valve alterations in hypertrophic cardiomyopathy sarcomere mutation carriers.
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe).
Response by Ho et al to Letter Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)".
The uptake of family screening in hypertrophic cardiomyopathy and an online video intervention to facilitate family communication.
Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy.
Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry.
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy.